结直肠癌在我国肿瘤发病率中位于第三位，死亡率位于第五位且有逐年提高的趋势，对于晚期结直肠癌的治疗 手段仍以化疗为主，化疗会引起相关脂肪肝的发生。肝转移是结直肠癌患者最常见的转移途径，有 50% 的结直肠癌最终会 发生肝转移，其中同时性肝转移发生率 15%~25%，其他为异时性转移。大多数研究发现，结直肠癌发生脂肪肝后肝转移发 生率会提高，但也有资料显示，脂肪肝会减少肝转移的发生率。结直肠癌常用的化疗方案及靶向治疗在既往的研究中都发 现有引起脂肪肝的可能性，且化疗药物引起脂肪肝的发生率随着化疗时间及周期数增多而加重，预防性的使用治疗胆汁淤 积类或降酶类药物会改善肝功能损伤的发生，治疗化疗相关性脂肪肝有可能会改善患者化疗肝损害的发生，从而提高治疗 疗效。发生脂肪肝后所需的术后残存肝体积增大，且由于肝脏质地发生变化，术中出血风险大大增加、止血难度增大，导 致手术的风险明显上升。探讨化疗相关性脂肪肝对结直肠癌肝转移具有非常现实的临床意义。

Context colorectal cancer is the third most common form of cancer and the fifth most frequent cause of cancer deaths in China and has a tendency to increase year by year. Primary treatment of advanced colorectal cancer still is chemotherapy, and chemotherapy can cause non-alcoholic hepatic steatosis. Hepatic metastasis is the most common metastatic pathway in colorectal cancer patients, and about 50% of colorectal cancer will eventually develop hepatic metastasis, among which colon cancer combined hepatic metastasis is about 15% to 25%, while others are metachronous liver metastases. The incidence of hepatic metastasis is higher in colorectal cancer with hepatic steatosis, but there is also evidence that hepatic steatosis which can reduce the incidence of liver metastasis. Chemotherapy and target therapy for colorectal cancer are commonly used in past studies have found that cause the hepatic steatosis, and the hepatic steatosis increased with the increase of chemotherapy time and period. Prevent therapy with cholestasis or enzymatic drugs can improve the liver function injury. If have hepatic steatosis, the postoperative residual liver volume increased, and due to the change of liver texture, the risk of intraoperative hemorrhage increased significantly and the difficulty of hemostasis increased, leading to a significant increase in the risk of surgery. Study hepatic steatosis cause by chemotherapy have an influence on therapy of hepatic metastasis of colorectal carcinoma has very realistic clinical significance.